Compare Stocks: STOK, LGND, CGON, and SRRK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$70.52 +1.3%	$74.16	$35.80 ▼ $80.97	$6.17B	0.24	908,221 shs	1.04 million shs
LGND Ligand Pharmaceuticals	$310.36 -1.2%	$291.22	$172.36 ▼ $326.63	$6.26B	1.11	221,888 shs	428,139 shs
SRRK Scholar Rock	$47.75 -2.8%	$52.34	$27.07 ▼ $61.76	$5.98B	0.67	2.16 million shs	1.07 million shs
STOK Stoke Therapeutics	$25.88 +1.5%	$30.12	$20.32 ▼ $40.22	$1.65B	1.23	809,579 shs	849,151 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+3.66%	-11.04%	-6.36%	-2.03%	+85.43%
LGND Ligand Pharmaceuticals	+4.17%	+8.28%	+11.98%	-0.63%	+85.07%
SRRK Scholar Rock	+1.03%	+2.01%	-15.00%	-10.67%	+26.79%
STOK Stoke Therapeutics	+2.82%	-9.09%	-19.35%	-22.07%	+5.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$70.52 +1.3%	$74.16	$35.80 ▼ $80.97	$6.17B	0.24	908,221 shs	1.04 million shs
LGND Ligand Pharmaceuticals	$310.36 -1.2%	$291.22	$172.36 ▼ $326.63	$6.26B	1.11	221,888 shs	428,139 shs
SRRK Scholar Rock	$47.75 -2.8%	$52.34	$27.07 ▼ $61.76	$5.98B	0.67	2.16 million shs	1.07 million shs
STOK Stoke Therapeutics	$25.88 +1.5%	$30.12	$20.32 ▼ $40.22	$1.65B	1.23	809,579 shs	849,151 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+3.66%	-11.04%	-6.36%	-2.03%	+85.43%
LGND Ligand Pharmaceuticals	+4.17%	+8.28%	+11.98%	-0.63%	+85.07%
SRRK Scholar Rock	+1.03%	+2.01%	-15.00%	-10.67%	+26.79%
STOK Stoke Therapeutics	+2.82%	-9.09%	-19.35%	-22.07%	+5.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.73	Moderate Buy	$87.78	24.47% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$337.89	8.87% Upside
SRRK Scholar Rock	2.94	Moderate Buy	$66.75	39.79% Upside
STOK Stoke Therapeutics	2.82	Moderate Buy	$44.25	70.98% Upside

Current Analyst Ratings Breakdown

Latest STOK, LGND, CGON, and SRRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	LGND Ligand Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$345.00
9/24/2026	SRRK Scholar Rock	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$76.00 ➝ $77.00
9/24/2026	LGND Ligand Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$358.00
9/23/2026	LGND Ligand Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$390.00 ➝ $397.00
9/21/2026	LGND Ligand Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/21/2026	SRRK Scholar Rock	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$70.00
9/21/2026	SRRK Scholar Rock	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$63.00 ➝ $70.00
9/15/2026	SRRK Scholar Rock	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/15/2026	SRRK Scholar Rock	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$72.00
9/15/2026	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$64.00
9/15/2026	SRRK Scholar Rock	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$60.00 ➝ $75.00

(Data available from 9/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,547.25	N/A	N/A	$9.33 per share	7.56
LGND Ligand Pharmaceuticals	$268.09M	23.08	$7.76 per share	40.00	$51.68 per share	6.01
SRRK Scholar Rock	N/A	N/A	N/A	N/A	$2.41 per share	N/A
STOK Stoke Therapeutics	$184.42M	9.06	N/A	N/A	$6.17 per share	4.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
LGND Ligand Pharmaceuticals	$124.45M	$9.35	33.19	37.17	2.54	67.88%	20.06%	11.68%	11/5/2026 (Estimated)
SRRK Scholar Rock	-$377.94M	-$3.45	N/A	N/A	N/A	N/A	-160.19%	-87.18%	11/13/2026 (Estimated)
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	11/3/2026 (Estimated)

Latest STOK, LGND, CGON, and SRRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/6/2026	Q2 2026	LGND Ligand Pharmaceuticals	$1.97	$2.37	+$0.40	$2.22	$61.30 million	$63.69 million
8/6/2026	Q2 2026	SRRK Scholar Rock	-$0.8405	-$0.84	+$0.0005	-$0.84	$3.33 million	N/A
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
LGND Ligand Pharmaceuticals	1.16	31.18	30.96
SRRK Scholar Rock	0.77	7.02	7.02
STOK Stoke Therapeutics	N/A	7.69	7.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
LGND Ligand Pharmaceuticals	91.28%
SRRK Scholar Rock	91.08%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
LGND Ligand Pharmaceuticals	5.60%
SRRK Scholar Rock	10.30%
STOK Stoke Therapeutics	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
LGND Ligand Pharmaceuticals	47	19.94 million	18.82 million	Optionable
SRRK Scholar Rock	289	121.79 million	109.24 million	Optionable
STOK Stoke Therapeutics	170	64.53 million	58.33 million	Optionable

STOK, LGND, CGON, and SRRK Headlines

Recent News About These Companies

Financial Contrast: Stoke Therapeutics (NASDAQ:STOK) & Invivyd (NASDAQ:IVVD)

September 27 at 5:44 AM | americanbankingnews.com

Bank of America Corp DE Makes New Investment in Stoke Therapeutics, Inc. $STOK

September 27 at 3:11 AM | marketbeat.com

Stoke Therapeutics, Inc. Announces Board Changes

September 23, 2026 | marketscreener.comM

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval ...

September 23, 2026 | marketscreener.comM

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

September 23, 2026 | businesswire.com

Stoke Therapeutics (NASDAQ:STOK) Shares Down 9% - What's Next?

September 23, 2026 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from Analysts

September 23, 2026 | americanbankingnews.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts

September 23, 2026 | marketbeat.com

Stoke Therapeutics stock holds gains after recent data update

September 19, 2026 | ad-hoc-news.deA

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - September 16, 2026

September 17, 2026 | biospace.comB

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

September 16, 2026 | businesswire.com

Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK

September 8, 2026 | marketbeat.com

Stoke Therapeutics, Inc. $STOK Shares Sold by Troluce Capital Advisors LLC

September 6, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK

September 5, 2026 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Insider Sells 5,545 Shares of Stock

September 4, 2026 | insidertrades.com

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of ...

September 3, 2026 | markets.businessinsider.com

Stoke Therapeutics (NASDAQ:STOK) Insider Sells $170,065.15 in Stock

September 3, 2026 | marketbeat.com

Stoke, Biogen report four-year zorevunersen data showing sustained seizure control

September 3, 2026 | ijr.comI

The Manufacturers Life Insurance Company Makes New Investment in Stoke Therapeutics, Inc. $STOK

September 3, 2026 | marketbeat.com

Stoke Therapeutics, Inc. $STOK Shares Acquired by Wellington Management Group LLP

September 2, 2026 | marketbeat.com

Stoke Therapeutics Inc 0GT

September 1, 2026 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

STOK, LGND, CGON, and SRRK Company Descriptions

CG Oncology NASDAQ:CGON

$70.52 +0.91 (+1.31%)

Closing price 04:00 PM Eastern

Extended Trading

$70.58 +0.06 (+0.08%)

As of 07:30 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Ligand Pharmaceuticals NASDAQ:LGND

$310.36 -3.74 (-1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$314.20 +3.83 (+1.24%)

As of 07:30 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Scholar Rock NASDAQ:SRRK

$47.75 -1.38 (-2.81%)

Closing price 04:00 PM Eastern

Extended Trading

$47.76 +0.01 (+0.01%)

As of 07:37 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Stoke Therapeutics NASDAQ:STOK

$25.88 +0.38 (+1.49%)

Closing price 04:00 PM Eastern

Extended Trading

$25.88 0.00 (-0.02%)

As of 07:30 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STOK, LGND, CGON, and SRRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STOK, LGND, CGON, and SRRK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STOK, LGND, CGON, and SRRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

STOK, LGND, CGON, and SRRK Company Descriptions

CG Oncology NASDAQ:CGON

Ligand Pharmaceuticals NASDAQ:LGND

Scholar Rock NASDAQ:SRRK

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STOK, LGND, CGON, and SRRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STOK, LGND, CGON, and SRRK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STOK, LGND, CGON, and SRRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

STOK, LGND, CGON, and SRRK Company Descriptions

CG Oncology NASDAQ:CGON

Ligand Pharmaceuticals NASDAQ:LGND

Scholar Rock NASDAQ:SRRK

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools